Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Next Previous
X
Search
Trial Profile

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PIONEER 5
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 31 May 2023 Results of a post-hoc analysis from clinical trials: PIONEER 1-5 and 8 assessing clinically relevant composite endpoints of HbA1c (glyclated haemogloblin) reduction published in the Diabetes Therapy
    • 29 Jun 2021 Data from PIONEER 1-5, 7 AND 8 were used to assess BW loss, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
    • 17 May 2021 Results of a pooled analysis of data from SUSTAIN 3 and PIONEER 1, 2, 5 studies assessing the effect of the two formulations of semaglutide vs comparators on hsCRP (an anti-inflammatory marker) presented at the 70th Annual Scientific Session of the American College of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top